Acumen Pharmaceuticals, INC 8-K filings

Acumen Pharmaceuticals announced its second quarter 2026 financial results and provided a business update, including expected topline results for its Phase 2 ALTITUDE-AD study in late 2026 and progress on its Enhanced Brain Delivery program.

Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) development candidates for Alzheimer's disease, leveraging a collaboration with JCR Pharmaceuticals.

Acumen Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Acumen Pharmaceuticals reported its first quarter 2026 financial results and provided a business update, highlighting progress in its Alzheimer's disease drug development programs and a cash runway into early 2027.

Acumen Pharmaceuticals reported full-year 2025 financial results and provided business updates, including anticipated late 2026 topline data for its lead Alzheimer's candidate and a mid-2027 IND filing for its Enhanced Brain Delivery program.

Acumen Pharmaceuticals raises $35.75 million in a private placement to advance its Enhanced Brain Delivery program, backed by strong preclinical data.

Acumen Pharmaceuticals provides a corporate presentation update, showcasing positive Phase 1 sabirnetug data, EBD program advancements, and a strong financial runway.

Acumen Pharmaceuticals reported third-quarter 2025 financial results, highlighted by a reduced net loss and progress in its Alzheimer's disease clinical programs, including sabirnetug and an Enhanced Brain Delivery therapy.

Acumen Pharmaceuticals announced the appointment of Dr. George Golumbeski, an industry veteran with over 30 years of experience, as the new Chairman of its Board of Directors, effective November 6, 2025.

Acumen Pharmaceuticals reported second-quarter 2025 financial results, highlighted by increased R&D expenses, a larger net loss, and continued progress in its Alzheimer's disease clinical programs, including a new Enhanced Brain Delivery collaboration.

Acumen Pharmaceuticals has entered a strategic collaboration with JCR Pharmaceuticals to develop an Enhanced Brain Delivery product for Alzheimer's disease, leveraging their respective expertise in amyloid beta oligomer-selective antibodies and blood-brain barrier-penetrating technology.

Acumen Pharmaceuticals, Inc. announced that its stockholders approved the election of three Class I directors and ratified Ernst & Young LLP as its independent auditor for 2025 at the Annual Meeting held on June 4, 2025.

Acumen Pharmaceuticals announces first quarter 2025 financial results and provides a business update on its Alzheimer's disease program, including the Phase 2 ALTITUDE-AD study with topline results expected in late 2026.

Acumen Pharmaceuticals announces completion of enrollment for its Phase 2 ALTITUDE-AD study, positive Phase 1 subcutaneous results, and a cash runway into the first half of 2027.

Acumen Pharmaceuticals announced its third quarter 2024 financial results, highlighted by progress in its Alzheimer's disease drug development program and a strong cash position.

Acumen Pharmaceuticals announced second quarter 2024 financial results and provided updates on their Alzheimer's drug development programs, including the initiation of a subcutaneous dosing study for sabirnetug.

Acumen Pharmaceuticals held its 2024 annual meeting, electing two Class III directors and ratifying Ernst & Young LLP as its independent auditor.

Acumen Pharmaceuticals reported its first quarter 2024 financial results and highlighted the initiation of a Phase 2 clinical trial for its Alzheimer's drug, sabirnetug.

Acumen Pharmaceuticals announced its full year 2023 financial results and provided a business update, highlighting positive Phase 1 clinical trial results and plans for Phase 2 and subcutaneous dosing studies in 2024.

Acumen Pharmaceuticals announced its cash runway extends into the first half of 2027 and plans to amend its Phase 2/3 study to a standalone Phase 2 study.

Acumen Pharmaceuticals has appointed James Doherty as President and Chief Development Officer, effective February 1, 2024, while also updating Daniel O'Connell's role to Chief Executive Officer.

Acumen Pharmaceuticals is progressing its Alzheimer's drug, ACU193, with positive Phase 1 results and plans for Phase 2 and subcutaneous trials in 2024.